Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01711034 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer
A Phase 1 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 1
- Development phase
- 145
- Enrollment target
NCT01711034 is a Phase 1 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 145 participants.
The verdict
NCT01711034, a Phase 1 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 145 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the safe and tolerable dose level of OPB-111077 for patients with advanced cancer.
Interventions
- DRUG OPB-111077
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 145 participants |
| Start Date | 2012-06 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01711034
The ClinicalTrials.gov registry entry for NCT01711034 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OPB-111077 is the first listed.
NCT01711034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01711034 about?
NCT01711034 is a clinical study titled "A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer". The primary objective of this study is to determine the safe and tolerable dose level of OPB-111077 for patients with advanced cancer.
What is the current status of trial NCT01711034?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2012-06. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01711034?
The interventions under investigation include: OPB-111077 (DRUG).
Who is sponsoring clinical trial NCT01711034?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.